The purpose of this study was to investigate whether specific combinations of polymorphisms in 5-fluorouracil (5-FU) metabolism-related genes were associated with outcome in 5-FU-based adjuvant treatment of colorectal cancer. Methods: We analyzed two cohorts of 302 and 290 patients, respectively, one cohort for exploratory analyses and another cohort for validating the exploratory analyses. A total of ten polymorphisms in genes involved in 5-FU pharmacodynamics and pharmacokinetics were studied. End points were disease-free survival (DFS) and overall survival. Multifactor dimensionality reduction was used to identify genetic interaction profiles associated with outcome. Results: Low-expression alleles in thymidylate synthase (TYMS) were associated with decreased DFS and overall survival (DFS:hazard ratio 
The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer 5-fluorouracil (5-FU) is widely used to treat solid tumors, including colorectal cancers. 5-FU cytotoxicity depends primarily on two active metabolites. Fluorodeoxyuridine monophosphate inhibits the thymidylate synthase (TYMS) enzyme [1] . The other metabolite, f luorouridine triphosphate, impairs RNA function and thereby induces cell toxicity [2, 3] . The inhibition of the TYMS enzyme is dependent on and enhanced by intracellular 5,10-methylenetetrahydrofolate ( Supplementary Figure 1; www.futuremedicine.com/ doi/suppl/10.2217/pgs.11.83) [1, 4] .
Increased sensitivity of cancer cell lines to 5-FU is correlated with decreased expression or activity of dihydropyrimidine dehydrogenase (DPYD), methylenetetrahydrofolate reductase (MTHFR) and TYMS and increased activity or expression of oratate phosporibosyltransferase (OPRT or UMPS) [5] [6] [7] [8] [9] [10] . Studies investigating the association of TYMS, DPYD, OPRT and MTHFR polymorphisms or expression with survival in adjuvant 5-FU-based treatment of colorectal cancer have yielded contradictory results, especially regarding TYMS and MTHFR [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Most studies investigate the association of individual polymorphisms with diseasefree survival (DFS) or overall survival (OS).
Theoretically, the 5-FU metabolic phenotype is better explained by multigene and pathwayoriented ana lysis rather than single gene ana lysis. Systematic multipolymorphism combinations can be constructed by two methods: phenotypic classifications of gene expression or enzyme activity based on combinations of functional polymorphisms, that is, if two genotypes at two different loci in the same gene decrease enzyme activity their simultaneous presence will decrease activity more than if either one is present alone, or through investigation of gene-gene interactions. One method of studying gene-gene interactions is the multifactor dimensionality reduction (MDR) method, which reveals interactions between genetic profiles and response. The basic concept behind the MDR methodology is that polymorphisms in one gene are only functional in the presence of other polymorphisms. This concept is known as nonlinear interaction or epistasis.
The purpose of this study was to investigate whether individual polymorphisms, haplotypes, phenotypic classifications based on functional polymorphisms and specif ic gene-gene interactions were associated with DFS. We used two independent cohorts treated with adjuvant 5-FU-based chemotherapy; one cohort for exploratory analyses and another cohort for validating the exploratory analyses. This analysis strategy has been successfully applied in a previous publication [25] . n Genotyping Extraction and genotyping methods for tissue and samples have been described elsewhere [15, 21, 22] . TYMS was genotyped using RFLP methods as detailed previously elsewhere [15, 22] . table 1 lists the ten studied polymorphisms, which were chosen based on functional effects. Genotypes were determined using the fluorogenic 5´-nuclease assay (TaqMan ® SNP Genotyping Assay made-to-order on an ABI 7900 HT, Applied Biosystems, CA, USA) [21] .
Methods
The reaction mix was as follows: 25 µl containing 10 ng DNA, 14 µl primer/probe mix with TaqMan ® Universal PCR Master mix (Applied Biosystems, CA, USA) according to the manufacturer's instructions. PCR amplification was carried out with an initial step of 95°C for 10 min followed by 40 cycles of 92°C for 15 s and 60°C for 1 min (Applied Biosystems 7900HT Sequence Detection System). The fluorescence profile of each well was measured in an Applied Biosystems 7900HT Sequence Detection System, and the results were analyzed with Sequence Detection Software (SDS 2.3, Applied Biosystems). Controls were included on each plate. Reproducibility was checked by regenotyping 10% of the samples with 100% agreement.
The greater number of failed genotyping attempts in the validation cohort is due to DNA Based on the variable number of tandem repeats (VNTRs), the G>C SNP in the 5'-UTR (VNTR SNP) and the 3'-UTR 6 bp insertion/deletion (ins/del) polymorphism, TYMS expression was classified as high, intermediate or low expression (table 2) . Studies have demonstrated that the TYMS VNTR and an insertion/deletion polymorphism are associated with mRNA stability and TYMS expression, with the three repeat and insertion alleles, respectively, being associated with increased TYMS expression, whereas the G>C base change in the second VNTR decreases the transcriptional activity of the TYMS gene [29] [30] [31] .
The polymorphisms in DPYD were combined additively, meaning that increasing the number of variant alleles was thought to correlate with decreasing DPYD activity.
n MDR method The MDR method, a nonparametric method, was used to study interaction between the polymorphisms in relation to toxicity [32] . This method is implemented in the MDR software, which was used for interaction analyses (version 2.0 b 8). Patients with missing data for polymorphisms were excluded from the ana lysis. We assumed that the patients with beneficial or detrimental genetic profiles had a DFS much longer or much shorter than median DFS. We chose top and bottom quartiles as they can be regarded as having exceptionally long or short survival, while still containing enough patients for meaningful ana lysis. We carried out two separate analyses, where patients in the top or bottom quartiles for DFS were considered as affected patients in the genetic interaction analysis. The ratio between patients in the top or bottom survival quartile to the rest of the patients for each genotype combination was evaluated. Combinations with more patients in shortest or longest quartile than other combinations were considered to be associated with a high chance of short or long DFS. This procedure was carried out across tenfold cross-validation samples to avoid over-fitting and was repeated for all possible combinations of two and three polymorphisms. The genotype combinations with the highest test sample accuracy and cross-validation consistency (fraction of correctly classified patients) were considered the combinations that best predicted outcome and were selected for further ana lysis.
n Statistics The primary end point was DFS, that is, recurrence of disease or death from disease, whatever occurred first. The secondary end point, OS, was defined as death from any cause. DFS and OS were measured from the date of intended curative resection to the date of event. Patients who were alive or had not relapsed at the last follow-up were censored at that time.
Differences in clinical variables between the two cohorts were analyzed using the chi-squared test or Mann-Whitney U test.
The associations of polymorphisms and all genetic classifiers with DFS and OS were assessed using univariable and multivariable Cox proportional hazards models. Adjustment was made for known predictive factors (age, sex, tumor grade and tumor stage) and cohort in the multivariable Cox proportional hazards models. Significance of individual factors and interaction terms were tested by log-likelihood statistics with nested models. Assumptions for the Cox ana lysis, that are linearity and proportional hazards, were checked for each variable using cumulative residuals; variables not fulfilling the assumptions were used as stratification variables. Survival differences between different groups were visualized using Kaplan-Meier curves.
All variables, including the genetic classifiers met the assumptions of the model except tumor stage; adjustment for tumor stage was carried out using it as a stratification variable. The basic design was that all statistical analyses were carried out on the exploration cohort and any significant associations were tested in the validation cohort.
Inferred haplotypes with more than 50% missing genotypes were set as missing data in ana lysis.
In the bootstrap procedure, the original set of data of size N became a parent population from which samples of size N were randomly drawn with replacement. All samples had identical stratification to the original sample in regards to the specific genotype combination. A total of 2000 bootstrap samples were created from the combined cohort and the aforementioned multivariable Cox regression was applied to each sample. Percent inclusion was used to determine the predictive importance of a variable because it was expected that an important variable would be included in the model for a majority of the bootstrap samples, defined as an inclusion rate of >65% [33] [34] [35] . The bootstrap-T interval was used to construct bootstrap confidence intervals (CIs) for the sample mean regression parameter for each genotype combination and expressed as hazard ratios (HRs).
Linkage disequilibrium between the relevant polymorphisms and Hardy-Weinberg equilibrium were calculated using Haploview v4.1. Phase 2.1.1. software for inferring individual haplotypes. All reported p-values are two-sided. All analyses were performed using the SAS Statistical Package Version 9.2 (SAS Institute Inc, NC, USA).
Results n Population characteristics & genotyping
The main differences in clinical variables between the two cohorts were in tumor characteristics (table 3) . The tumors in the validation cohort had higher stage and grade; follow-up and the numbers of events were similar between the two cohorts.
The genotype distribution of MTHFR677, DPYD 85T>C and the TYMS polymorphisms were different between the cohorts. DPYD 1905 +1G>A was excluded from the analysis due to too low allele frequency. All the genotypes in the exploration cohort were in Hardy-Weinberg equilibrium.
n Genotype & haplotype associations None of the individual polymorphisms were associated with DFS (table 4 & Supplementary table 1) . There was linkage disequilibrium between MTHFR677 and MTHFR1298 and to a lesser degree between DPYD 85T>C and DPYD 496A>G and between the TYMS VNTR and ins/del polymorphisms (Supplementary table 2) . These haplotypes were chosen for further analysis. None of the haplotypes were associated with DFS. Diplotype, defined as a pair of haplotypes, ana lysis revealed that patients harboring either the TYMS 2R-del/2R-del or 2R-del/2R-ins diplotypes had worse DFS compared with other patients (DFS exploration HR: 2.65 [1. .65]; p = 0.004) (Supplementary Figure 2) . These two diplotypes were combined due to only one patient harboring the 2R-del/2R-del in the exploration cohort (table 5) n Gene-gene interactions The functional classifications of MTHFR, TYMS or DPYD expression were not associated with DFS (table 2) .
In the MDR ana lysis all of the polymorphisms and the functional classifications of MTHFR, TYMS and DPYD were included as variables.
As mentioned previously, the best two-way and three-way classifiers for long-term and shortterm DFS were evaluated. Only a two-way genetic classifier (Figure 1 Figure 2) . The MDR classifier, is a dichotomous variable, where all the shaded cells in Figure 1 , are considered to be the same group. 
Discussion
We were able to confirm the hypothesis that combinations of genotypes may create predictive variables associated with DFS and OS that are more robust than individual polymorphisms as demonstrated by the independent validation of our genotype combinations and the irreproducible associations of individual SNPs with DFS (Supplementary table 1) . We found that low-expression diplotypes in TYMS were associated with decreased DFS and OS in both cohorts with a doubling of the HR. The MDR-derived classifier was associated with improved DFS in both cohorts with a 40% decrease in the HR compared with the reference groups. At first, the association of low expression of T YMS with decreased DFS seems counterintuitive. However, several clinical studies evaluating mRNA expression or protein expression corroborate this finding. High TYMS expression has been associated with early disease recurrence and death in patients receiving surgery only [11, 14, [36] [37] [38] [39] . Accordingly, comparisons of patients treated with surgery only and patients who also received 5-FU-based adjuvant therapy have shown that patients with high TYMS expression have improved outcome from 5-FU-based chemotherapy [11, 36, 37, 39, 40] . By contrast, patients with low tumoral TYMS have no improved outcome from adjuvant 5-FU therapy [36, 37, 39, 40] or even worse outcome from such treatment [11] . Investigations on polymorphisms have shown diverging results, some indicate that high-expression alleles are associated with improved DFS or OS [15, 16, 41] , while others have found opposite results [19, 42, 43] . This only applies to adjuvant treatment of colorectal cancer, as in metastatic cancer, high TYMS mRNA expression is associated with decreased survival [14] . The TYMS VNTR SNP did not enhance classification based on TYMS VNTRs and 3´UTR polymorphisms, which may be expected since only the VNTR and 3´UTR polymorphisms have been associated with increased TYMS expression in tumor tissues [29, 31] . In summary, TYMS is both a prognostic and predictive marker; patients with low TYMS expression may not benefit substantially from 5-FU-based adjuvant treatments and have a better outcome than patients with high TYMS expression. The regimens used in our cohorts were bolus regimens; studies indicate that the mechanisms of action may be different depending on whether a bolus or continuous infusion regimen is used. Bolus regimens may predominantly work through perturbation of RNA function whereas continuous regimens primarily work through TYMS inhibition [44] . Thus the relevance of our findings for all regimens cannot be deduced directly from our study.
The ratio of TYMS:DPYD has been investigated in several clinical studies assuming to represent the ratio between T Y MS concentration and catabolism. Low TYMS and DPYD expression together has been associated with improved DFS or OS in three studies [5, 12, [45] [46] [47] ; a high TYMS:DPYD ratio has been associated with decreased survival in patients treated with surgery alone and in patients treated adjuvantly [12, 48] and the combination of low TYMS and high DPYD expression together has been associated with decreased survival in adjuvantly treated patients in one study [49] . The presence of genetic interactions in the 5-FU metabolism pathway are evidenced by the previously referenced studies in a general way, but validation of specific genetic interactions require specific reports aimed at evaluating these specific interactions. The associations revealed by applying the MDR algorithm are statistical interactions that need further validation in biological systems and have to be replicated in other patient populations.
The strengths in our study design include large populations, homogenous treatments and the replication of our results in an independent validation cohort. Using an exploration versus validation cohort design should minimize the detection of false or random associations.
The limitations of the study are that we cannot account for whether tumor genotypes are representative of germline genotypes in the validation cohort, however, several studies have demonstrated excellent concordance between germline and tumor tissue genotypes [50] . In our study the only indication of loss of heterogeneity is for TYMS genotypes, but the consequent erroneous genotype assignment would only decrease the association. The differences in frequency for the two cohorts concerning MTHFR 677C>T and DPYD 85T>C polymorphisms do not seem to be due to loss of heterozygosity as the other genotypes within these genes are similar. This discrepancy could be explained by patients being from different geographical regions or random differences. For MTHFR677, it has been shown that the genotype frequencies vary with geographical regions both within and outside of Europe [51] . Other possible sources of bias are differences in reference groups in the two cohorts; the composite nature of the validation cohort; differences in tumor staging and grade; and in relation to OS treatment heterogeneity after relapse.
The bootstrap procedure can, to some degree, address these latter weaknesses and provide an internal validation strategy for the combined cohort. In the bootstrap samples we had the same genotype combinations with the same number of patients in each genotype stratum as the original population, but the random samples with replacement create samples with different cohort characteristics. This gives an opportunity to test whether the associations remain stable under different cohort characteristics. The high inclusion rates of the genotype combinations and almost identical estimates compared with the original ana lysis support the discernment that we have identified independent predictive markers.
The biological significance of the genotype combinations cannot be directly derived from our results, but high TYMS expression in normal tissues may be protective against certain toxicities. Furthermore, the MDR combination suggests that decreasing DPYD activity with decreasing TYMS activity, defined by the TYMS VNTR SNP, is associated with higher DFS. However, as already mentioned, MDR identifies statistical interaction and not necessarily a biological interaction, so care should be applied in making an overt biological interpretation of the MDR classifier.
In conclusion, we have provided evidence for three findings. First, individual polymorphisms were not reproducibly associated with DFS and OS. Second, low-expression diplotypes in TYMS were associated with decreased DFS and OS. Third, specific genotype interactions in DPYD and TYMS were associated with improved DFS.
Executive summary
The clinical efficacy of 5fluorouracil may depend on interactions of polymorphisms rather than individual polymorphisms.
Methods
Combinations of polymorphisms were derived from haplotype structures and the multifactor dimensionality reduction method. Survival analyses using diseasefree survival and overall survival as outcomes were conducted. These associations were analyzed in an exploration cohort and confirmed in a replication cohort.
Results
Our results suggest that lowexpression diplotypes in TYMS and the interaction between DPYD allele score and the TYMS variable number of tandem repeats polymorphism is associated with diseasefree survival and possibly overall survival in adjuvant treatment of colorectal cancer.
Conclusion
Specific combinations of functional polymorphisms in DPYD and TYMS were demonstrated to be associated with diseasefree survival and overall survival in patients receiving adjuvant 5fluorouracilbased treatment. Specifically, high TYMS expression alleles seem to be associated with decreased diseasefree survival. The first paper to show the functional consequence of the 6 bp insertion/deletion polymorphism in the thymidylate synthethase 3´-UTR.
